MD Anderson supports FDA proposal to prohibit menthol cigarettes
The University of Texas MD Anderson Cancer Center strongly encourages endorsement of the Food and Drug Administration (FDA) proposed rules to prohibit menthol cigarettes and flavored cigars.
The FDA banned the use of flavors in cigarettes in 2009, except for menthol. Today’s announcement represents a historic step closer to removing menthol cigarettes from the market. Once finalized, the product standards are...
High-fiber diet associated with improved progression-free survival and response to immunotherapy in melanoma patients
Patients with melanoma who reported eating more fiber-rich foods when they began immunotherapy treatment survived longer without cancer growth...
Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival benefit for patients with...
Active Living After Cancer program improves physical functioning of breast cancer survivors
Breast cancer survivors who participated in Active Living After Cancer, an evidence-based 12-week group program, markedly increased their physical activity and ability to accomplish the basic pursuits of daily life, researchers from The University of Texas MD Anderson Cancer Center reported today in Cancer. The results show the program could serve as a model to deliver a community-based physical activity program to minority and medically...
MD Anderson launches community-led Be Well™ Acres Homes initiative
With the launch of Be Well™ Acres Homes, The University of Texas MD Anderson Cancer Center unites more than 30 organizations, alongside community...
Classifying EGFR mutations by structure and function offers better way to match non-small cell lung cancer patients to treatments
Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations...
Novel immunotherapy combination produces durable response in frontline metastatic melanoma
A Phase II cohort from the international PIVOT-02 study has shown the combination of interleukin-2 (IL-2) pathway agonist bempegaldesleukin...
Study identifies gut microbes associated with toxicity to combined checkpoint inhibitors in melanoma patients
Researchers from The University of Texas MD Anderson Cancer Center found specific intestinal microbiota signatures correlate with high-grade...
Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer
ABSTRACT #9003
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib...
MD Anderson and other top U.S. cancer centers call for urgent action to get cancer-preventing HPV vaccination back on track
The University of Texas MD Anderson Cancer Center has united with fellow National Cancer Institute (NCI)-Designated Cancer Centers and partner...
MD Anderson researchers recognized by AACR
Three researchers from The University of Texas MD Anderson Cancer Center have been honored by the American Association for Cancer Research...
Study defines small-cell lung cancer subtypes and distinct therapeutic vulnerabilities for each type
Researchers from The University of Texas MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell...